Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Oscar S. Breathnach is active.

Publication


Featured researches published by Oscar S. Breathnach.


Annals of Surgery | 2007

Electrochemotherapy: Aspects of Preclinical Development and Early Clinical Experience

John O. Larkin; C. Collins; Simon Aarons; Mark Tangney; Maria C. Whelan; Seamus O'Reily; Oscar S. Breathnach; Declan M. Soden; Gerald C. O'Sullivan

Objective:To develop an optimized, reproducible system of electrochemotherapy, and to investigate its clinical application in patients with cutaneous or subcutaneous recurrences of inoperable or progressive disease recalcitrant to current anticancer treatments. Background:Electrochemotherapy is the application of electric pulses to tumor tissue, rendering the cell membranes permeable to otherwise impermeant or poorly permeant anticancer drugs. This facilitates a potent local cytotoxic effect. Study Design:The optimal parameters for electrical pulses and bleomycin concentration were obtained in vitro and then applied to tumors derived from 4 histologically distinct human cancer cell lines (7860, PC3, OE19, MCF-7) established in athymic nude mice. Comparison was made with tumors that received bleomycin alone, electric pulses alone, and untreated controls. The optimized electrochemotherapy was then applied to patients with cutaneous or subcutaneous tumors, of any histologic type, recurrent or metastatic and unresponsive to standard chemotherapy and/or radiotherapy regimens. Tumors were assessed at monthly intervals to determine response to the treatment. Results:In vivo: Using the optimal parameters ascertained in vitro, all tumors treated by electrochemotherapy with bleomycin (n = 24) had significantly regressed (P < 0.001, all 4 lines) compared with control tumors (n = 72). Twelve tumors completely regressed (50%) following a single application, with 12 partial regressions (50%). Clinical: In 30 patients (111 tumors), none of the treated tumors progressed. Sixty percent of tumors (66 of 111) showed complete regression, 22% (24 of 111) partial response, and 18% (21 of 111) no change. Electrochemotherapy was more effective in smaller tumors (<3 cm), 71% (64 of 90) showing complete regression, 20% (18 of 90) partial response, and 9% (8 of 90) no change. Conclusions:Electrochemotherapy parameters optimized in vitro are applicable in vivo. This treatment is effective in athymic nude mice for all histologic types indicating a nonimmunologic mode of action. In clinical application, electrochemotherapy is an effective, safe, and reproducible therapy. Patients with cutaneous or subcutaneous tumors previously refractory to surgical intervention, systemic chemotherapy, and/or radiotherapy responded successfully irrespective of histologic type.


Journal of Surgical Research | 2004

Prevalence of bone marrow micrometastases in esophagogastric cancer patients with and without neoadjuvant chemoradiotherapy

Paul Ryan; Seán McCarthy; Jacquie Kelly; J. Kevin Collins; Colum P. Dunne; Liam Grogan; Oscar S. Breathnach; Fergus Shanahan; P.Declan Carey; Thomas N. Walsh; Gerald C. O’Sullivan


Ejc Supplements | 2006

Effective treatment of an extensive recurrent breast cancer which was refractory to multimodal therapy by multiple applications of electrochemotherapy

Maria C. Whelan; John O. Larkin; C. Collins; James Cashman; Oscar S. Breathnach; Declan M. Soden; Gerald C. O’Sullivan


Journal of Clinical Oncology | 2017

Metastatic ACTH-producing pituitary carcinoma managed with combination pasireotide and bevacizumab following failure of temozolamide therapy: A case report.

Lynda M. O'Riordan; Megan Greally; Niamh Coleman; Oscar S. Breathnach; Bryan T. Hennessy; Chris Thompson; William Grogan


Journal of Clinical Oncology | 2017

Effect of somatic mutations in the four genes of the HER family on occurrence in HER2-positive breast cancer, cell proliferation rates, and resistance to HER2-targeted therapies in vitro.

Naomi Elster; Alex J. Eustace; Yue Fan; Jarushka Naidoo; Joanna Fay; Elaine Kay; Aoife Carr; Oscar S. Breathnach; Patrick G. Morris; William Grogan; Arnold Dk Hill; Colm Power; Michael J Allen; Susan Kennedy; John Crown; William M. Gallagher; Sinead Toomey; Bryan T. Hennessy


Journal of Clinical Oncology | 2017

A 10-year review of primary CNS lymphoma treatments and outcome: The Irish experience.

Scheryll Paula Alken; MinYuen Teo; Richard Martin Bambury; Mohd Syahizul Nuhairy Mohd Sharial; Anuradha Jayaram; Francesca Brett; Catherine Keohane; Michael Farrell; Maccon Keane; Derek G. Power; Eugene J. Moylan; William Grogan; Seamus O'Reilly; Oscar S. Breathnach


Journal of Clinical Oncology | 2017

Single-agent bevacizumab for recurrent high-grade glioma.

Megan Greally; Karen A. Cadoo; Niamh Coleman; Michelle O'Brien; Lynda M. O'Riordan; William Grogan; Oscar S. Breathnach


Journal of Clinical Oncology | 2017

Clinical, pathologic, and radiologic response in patients with neurofibromatosis type 2 (NF2) undergoing bevacizumab treatment.

Niamh Coleman; Megan Greally; Lynda O' Riordan; Teresa Doyle; Oscar S. Breathnach; William Grogan


Journal of Clinical Oncology | 2016

Sunitinib scheduling in metastatic renal cell cancer: A single-center experience.

Sarah Louise Picardo; Dearbhaile Catherine Collins; Amnah Al Khamis; Victoria Teresa Mallett; Niamh M. Keegan; Irnani Ismail; Bryan T. Hennessy; Oscar S. Breathnach; William Grogan; Patrick G. Morris


Age and Ageing | 2016

051EDMONTON FRAIL SCALE AS A PREDICTOR OF ADVERSE EVENTS IN OLDER PATIENTS UNDERGOING SYSTEMIC CANCER THERAPY IN IRELAND

Michelle O'Brien; Victoria Teresa Mallett; Mary Coghlan; Daphne Yen; Elisabeth Doran; David Williams; Anne M. Horgan; Bryan T. Hennessy; Oscar S. Breathnach; Liam Grogan; Patrick G. Morris

Collaboration


Dive into the Oscar S. Breathnach's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Megan Greally

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Niamh Coleman

The Royal Marsden NHS Foundation Trust

View shared research outputs
Top Co-Authors

Avatar

C. Collins

University College Cork

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge